fda warning letters glp-1 compounding october 2025 unleashes to firms selling compounded GLP-1s News Archives – Partnership for

The message is clear: treating obesity effectively means supporting continuity of care, personalization, and equity in access to chronic weight-management therapies

The success of scientific researches depends on the quality research material and documents

The FDA added it to injectable semaglutide in January 2025, and it climbs the dose axis like everything else. Burning or tingling skin tracks the dose, not the weight lost, and an active-comparator study put the risk about twice that of another weight-loss drug. The mechanism is unsettled: the tempting "it is the drugs signaling arm" story is ruled out, because the strongest GLP-1 signaler in the class carries no such signal

Effect of side-chain shortening on the physiologic properties of bile acids: hepatic transport and effect on biliary secretion of 23-nor-ursodeoxycholate in rodents